ReviewInternational journal of molecular sciences2022
From Dukes-MAC Staging System to Molecular Classification: Evolving Concepts in Colorectal Cancer.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Alteration of miR-21 and miR-24 expression: biomarker for early detection of synchronous metastases in colorectal cancer: a cross-sectional study in Indonesia.Intestinal research · 2026Article
- Integrating Clinical and Molecular Insights: CTPS1 as a Key Biomarker of Tumor Progression and Prognosis in Colorectal Adenocarcinoma.Applied immunohistochemistry & molecular morphology : AIMM · 2026Article
- Perforin and Granulysin-Mediated Cytotoxicity in Colorectal Cancer Patients.Medicina (Kaunas, Lithuania) · 2026Article
- Taxonomic Profiling of Systemic Inflammatory Parameters as Predictors of Tumor Progression in Primary Colorectal Cancer.Journal of clinical medicine · 2025Article
- Advanced hydrogel material for colorectal cancer treatment.Drug delivery · 2025Review
- Clinicopathological Implications of Maspin, CD8, and PD-L1 Expression in Liposarcomas.Current issues in molecular biology · 2025Article
- Downregulation of the Tumor Suppressor P53 Gene associated with the Progression of Clinical Staging and the Incidence of Distant Metastasis in Indonesian Colorectal Cancer.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025Article
- Advancing Colorectal Cancer Diagnostics from Barium Enema to AI-Assisted Colonoscopy.Diagnostics (Basel, Switzerland) · 2025Review
- The paradoxical role of SERPINB5 in gastrointestinal cancers: oncogene or tumor suppressor?Molecular biology reports · 2025Review
- Quality of life outcomes in colorectal cancer survivors: insights from an analytical study at a tertiary cancer center-Qatar.Frontiers in oncology · 2025Article
- Stage-based colorectal cancer prediction on uncertain dataset using rough computing and LSTM models.Scientific reports · 2024Article
- Expression Pattern of PDE4B, PDE4D, and SFRP5 Markers in Colorectal Cancer.Medicina (Kaunas, Lithuania) · 2024Article
- Markers of Epithelial-Mesenchymal Transition and Mucinous Histology Are Significant Predictors of Disease Severity and Tumor Characteristics in Early-Onset Colorectal Cancer.Diagnostics (Basel, Switzerland) · 2024Article
- UHPLC-HRMS-based Multiomics to Explore the Potential Mechanisms and Biomarkers for Colorectal Cancer.BMC cancer · 2024Article
- Serum Selenium Concentration as a Potential Diagnostic Marker for Early-Stage Colorectal Cancer: A Comparative Study.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Review
- Protein prognostic biomarkers in stage II colorectal cancer: implications for post-operative management.BJC reports · 2024Review
- Weighing the benefits of lymphadenectomy in early-stage colorectal cancer.Annals of surgical treatment and research · 2023Review
- Molecular Diagnostics, Pathology and Biomarkers of Gastrointestinal Neoplasms.International journal of molecular sciences · 2023Article
- Molecular subtyping in colorectal cancer: A bridge to personalized therapy (Review).Oncology letters · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This historical review aimed to summarize the main changes that colorectal carcinoma (CRC) staging systems suffered over time, starting from the creation of the classical Duke's classification, modified Astler-Coller staging, internationally used TNM (T-primary tumor, N-regional lymph nodes' status, M-distant metastases) staging system, and ending with molecular classifications and epithelial-mesenchymal transition (EMT) concept. Besides currently used staging parameters, this paper briefly presents the author's contribution in creating an immunohistochemical (IHC)-based molecular classification of CRC. It refers to the identification of three molecular groups of CRCs (epithelial, mesenchymal and hybrid) based on the IHC markers E-cadherin, β-catenin, maspin, and vimentin. Maspin is a novel IHC antibody helpful for tumor budding assessment, which role depends on its subcellular localization (cytoplasm vs. nuclei). The long road of updating the staging criteria for CRC has not come to an end. The newest prognostic biomarkers, aimed to be included in the molecular classifications, exert predictive roles, and become more and more important for targeted therapy decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.